RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.06 · Revenue $1.06M · 1 analysts
Est. EPS $-0.06 · Revenue $1.34M · 1 analysts
Est. EPS $-0.26 · Revenue $3.88M · 2 analysts
Est. EPS $-0.06 · Revenue $1.54M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $1.1M | +2511.6% | +61.5% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-11.2M | -26.7% | +17.3% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +70.9% | -29.1% | -1.0% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -1114.0% | +95.6% | +42.8% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -994.5% | +95.1% | +48.8% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-11.0M | -20.1% | +20.8% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -977.3% | +95.4% | +50.9% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 3.9% | -37.0% | +74.7% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 4.02x | -1.9% | -19.7% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $8.1M | -0.3% | -17.8% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.32 vs -0.27 | -20.0% | -0.06 vs -0.06 | +5.4% |
| Revenue Surprise | $1.1M vs $1.3M | -13.9% | $909000 vs $703750 | +29.2% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| May 19, 2026 | VOLL MARK | officer: Chief Financial Officer | Common Stock | A | 25,000 | $0.79 |
| Apr 3, 2026 | Bagai Shaun | director, officer: Chief Executive Officer | Stock Option | A | 946,107 | $0.98 |
| Apr 3, 2026 | VOLL MARK | officer: Chief Financial Officer | Common Stock | A | 80,000 | — |
| Apr 3, 2026 | Gentry Leesa | officer: Chief Clinical Officer | Stock Option | A | 128,550 | $0.98 |
| Apr 3, 2026 | Agah Ramtin | director, officer: Chief Medical Officer | Stock Option | A | 621,727 | $0.98 |
Operator: Good afternoon. I will be your conference call operator today. Please note that today's call is being recorded. There will be a Q&A session following management's presentation. I will now turn the call over to Valter Pinto, managing director of KCSA Strategic Communications. Please go ahead. Valter Pinto: Thank you, operator. Good afternoon, welcome, everyone, to the RenovoRx Second Quarter 26. Financial Results Conference Call. I am joined today by members of our leadership team, including Shaun Bagai, Chief Executive Officer Doctor. Ramtin Agah, Chief Medical Officer executive chair and founder and Mark Voll, chief financial officer. Before we begin, I would like to remind everyone that statements made during today's call contain or may contain forward looking statements. Covered by the Safe Harbor provisions and the Private Securities Litigation Reform Act of 2,000, And applicable federal securities laws. These statements, including statements regarding RenovoRx clinical and commercial plans, strategies and estimates, or expectations of financial or operational performance, including revenue, are based on management's current plans and assumptions, and actual results may differ materially. Please refer to our filings with the SEC, including our Form 10 Q for the ended 06/30/2026 for detailed discussion of the risks and uncertainties facing RenovoRx. With that, I would now like to turn the call over to our Chief Executive Officer, Shaun Bagai. Shaun R. Bagai: Thank you, Valter, and good afternoon, everyone. Over the past several quarters, we set out 3 milestones for RenovoRx. And this quarter, we delivered on all 3. First, revenue growth. The second quarter was a record revenue quarter, our strongest to date. Second, commercial momentum. We activated new commercial cancer centers at a pace ahead of our internal targets. And third, expansion beyond locally advanced pancreatic cancer. For the first time, a treating physician chose RenovaCath to deliver therapy to a patient with a different solid tumor. We told our investors we were going to achieve these goals, and we delivered. Last quarter, we spoke openly about the meaningful progress we have made on the commercialization of RenovaCath. Shifting our narrative from concept to execution and growth. This quarter shows our commercial execution in action. With our highest quarterly revenue we could not be more excited about our future. Our job now is to keep delivering quarter after quarter. For the second quarter ended 06/30/2026, RenovoRx generated record revenue of $909 thousand our strongest quarterly performance to date. Increasing approximately 61% sequentially and approximately 115% year over year. To put this performance in perspective, our second quarter revenue alone represented approximately 83% of our entire full year 2025 revenue of $1.1 million. This is a direct measurable result of the commercial model we have described. More active commercial cancer center customers more …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Shaun R. Bagai | Chief Executive Officer, Secretary & Director | USD 814,279 | Male | 1977 | Active |
Leesa Gentry | Chief Clinical Officer | USD 532,594 | Female | 1970 | Active |
Ronald Kocak | VP of Finance & Controller | USD 447,030 | Male | 1958 | Active |
Ramtin Agah | Founder, Executive Chairman & Chief Medical Officer | USD 432,708 | — | 1966 | Active |
Mark Voll | CFO & Principal Accounting Officer | — | Male | 1955 | Active |
Robert Strasser | Vice President of Operations and R&D | — | Male | — | Active |
Ryan Witt | Senior Vice President and Head of Corporate Strategy & Partnerships | — | Male | — | Active |
RenovoRx NASDAQ: RNXT executives and physician speakers discussed the treatment landscape for locally advanced pancreatic cancer, the company's Trans-Arterial Micro-Perfusion, or TAMP, platform, and commercialization progress for its RenovoCath delivery device during a webinar hosted by JonesTrading.
RenovoRx NASDAQ: RNXT reported record second-quarter revenue as it expanded its commercial cancer-center network and advanced its clinical program for locally advanced pancreatic cancer.
RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.08 per share a year ago.
Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M First Treatment Delivered with RenovoCath ® in Patient with Sarcoma in Clinical Setting, Marking Expansion of Device to Other Solid Tumors Phase III TIGeR-PaC Trial Reaches Full Enrollment; Completion of Trial Expected in First Half 2027 with Topline Data Readout Expected in Second Half 2027 Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif.
MOUNTAIN VIEW, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, is pleased to announce completion of enrollment in the Company's Phase III TIGeR-PaC trial in locally advanced pancreatic cancer (LAPC).
